The company
Intellia Therapeutics, Inc.
NTLA · Nasdaq
Health CareGenomics & Gene EditingNot moving yetSynthetic Biology / TechBio
NTLA stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 13.0% below that average now. Genomics & Gene Editing: 20% of its 5 stocks in an uptrend (−20 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 14
- Industry in uptrend
- 20% -20 in 4 wk
- Insider buys, 12 months
- $2.8M
- Insider sales, 12 months
- $3.5M
- Officials’ trades on record
- 16
- Institutions holding
- 309 (+25)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.
17 Apr – 16 Oct
Genomics & Gene Editing: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
16 disclosed lines: House 10, Senate 6, executive 0; 4 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Thomas R. Carper Senate: U.S. Senate eFDSenator | soldspouse | $1k–$15k | 25 Aug 2023filed 5 Sep 2023 |
| Thomas R. Carper Senate: U.S. Senate eFDSenator | boughtspouse | $1k–$15k | 22 May 2023filed 30 Jun 2023 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $15k–$50k | 28 Feb 2022filed 3 Mar 2022 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 29 Oct 2021filed 30 Oct 2021 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 20 Sep 2021filed 1 Oct 2021 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 21 Jul 2021filed 7 Aug 2021 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 15 Jan 2021filed 31 Jan 2021 |
| Thomas R. Carper Senate: U.S. Senate eFDSenator | boughtspouse | $1k–$15k | 20 Nov 2020filed 17 May 2021 |
| Thomas R. Carper Senate: U.S. Senate eFDSenator | boughtspouse | $1k–$15k | 20 Nov 2020filed 2 Dec 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 18 Nov 2020filed 1 Dec 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 26 Aug 2020filed 6 Sep 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 10 Jul 2020filed 9 Aug 2020 |
Insiders
Buy orders, 12 months1
Sale orders, 12 months16
Buyers · sellers1 · 7
| Who | Did | Shares | Traded |
|---|---|---|---|
| Michael P. DubeVP, Chief Accounting Officer | sold | 1,864at $12.43 | 2 Oct 2026filed 6 Oct 2026 |
| John M. LeonardPresident and CEO | sold | 2,785at $13.00 | 21 Aug 2026filed 24 Aug 2026 |
| John M. LeonardPresident and CEO | sold | 19,890at $12.60 | 20 Aug 2026filed 24 Aug 2026 |
| Edward J. Dulac IIIEVP, Chief Financial Officer | sold | 8,111at $11.25 | 22 Jul 2026filed 24 Jul 2026 |
| Edward J. Dulac IIIEVP, Chief Financial Officer | sold | 4,677at $18.00 | 2 Jul 2026filed 6 Jul 2026 |
| Michael P. DubeVP, Chief Accounting Officer | sold | 2,641at $16.78 | 1 Jul 2026filed 6 Jul 2026 |
| Eliana ClarkEVP, Chief Technical Officer | sold | 607at $13.78 | 2 Mar 2026filed 3 Mar 2026 |
| James BastaEVP, General Counsel | sold | 1,211at $13.78 | 2 Mar 2026filed 3 Mar 2026 |
| Michael P. DubeVP, Chief Accounting Officer | sold | 2,989at $9.21 | 5 Jan 2026filed 7 Jan 2026 |
| Edward J. Dulac IIIEVP, Chief Financial Officer | sold | 6,379at $9.21 | 5 Jan 2026filed 7 Jan 2026 |
| Eliana ClarkEVP, Chief Technical Officer | sold | 9,515at $9.21 | 5 Jan 2026filed 7 Jan 2026 |
| David LebwohlEVP, Chief Medical Officer | sold | 11,903at $9.21 | 5 Jan 2026filed 7 Jan 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders309+25 on the quarter
New · exited53 · 28
Reported value$2.4B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| ARK Investment Management LLCadded · filed 14 Aug 2026 | 16,875,684$285.5M | +2,366,437+16.3% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 15,409,023$260.7M | +3,253,217+26.8% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 9,234,987$156.3M | +2,312,311+33.4% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 7,332,401$124.1M | +1,109,076+17.8% |
| D. E. Shaw & Co., Inc.added · filed 14 Aug 2026 | 6,443,323$109.0M | +715,146+12.5% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 6,028,586$102.0M | +944,481+18.6% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 5,235,348$88.6M | +529,447+11.3% |
| FMR LLCadded · filed 13 Aug 2026 | 4,773,034$80.8M | +2,705,812+130.9% |
| RA CAPITAL MANAGEMENT, L.P.new · filed 14 Aug 2026 | 4,526,926$76.6M | +4,526,926 |
| REGENERON PHARMACEUTICALS, INC.unchanged · filed 7 Aug 2026 | 3,702,995$62.7M | 00.0% |
31 Mar 2023 – 30 Jun 2026
News
Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory Functionsrttnews.com · 13 Oct 2026Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officermanilatimes.net · 13 Oct 2026Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?insidermonkey.com · 10 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.